In this study, we explored a large cohort of nivolumab-treated NSCLC patients in daily clinical practice and studied whether patients with SNPs in the PD-1 and PD-1-related genes experienced toxicity more (or less) frequently or severely than other patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.